A deal between the two pharmaceutical giants could be valued at more than $60 billion, a published report says. More: continued here
A deal between the two pharmaceutical giants could be valued at more than $60 billion, a published report says. More: continued here
Microsoft is also on the list. More: continued here
The trading panel says GE faces a big decision on its dividend. More: continued here
Cramer says the a stock is a great buy under $20. More: continued here